Shares of MeiraGTx Holdings shares reached a 52-week high after the company said 11 children treated to date in a drug study gained visual acuity after treatment. The stock was recently up 9.1%, to $7 ...

MeiraGTx stock rose after publishing promising results from the first human trial using gene therapy to treat ...

Orlando, FL - Micro Medical Devices (MMD), a longstanding innovator in the field of ophthalmic diagnostic technology, is set to showcase its latest advancements at Vision Expo East 2025 in Orlando, ...

Eleven children who were legally blind at birth all gained visual acuity after receiving MeiraGTx's investigational gene ...

Test your eyesight and colour vision with this fun optical illusion challenge. Spot the hidden number in a colourful circle ...

Holdings announced the publication of results from the first-in-human interventional study to treat children with ...

Phacovitrectomy for epiretinal membrane and cataract leads to higher prediction errors compared with standalone cataract surgery.

Patients who underwent bilateral treatment experienced a higher rate of clinically relevant recovery, the authors reported.

Hydrophilic and hydrophobic IOLs demonstrate similar visual outcomes and inflammatory responses in patients with and without uveitis.

Topline results for COAST are anticipated in early Q2 2025, with ShORe results expected mid-2025.

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

A multicenter study led by researchers from the State Key Laboratory of Ophthalmology in China has characterized a distinct ...